Haven Capital Group Inc. Sells 1,532 Shares of IDEXX Laboratories, Inc. $IDXX

Haven Capital Group Inc. decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 12,137 shares of the company’s stock after selling 1,532 shares during the quarter. IDEXX Laboratories makes up approximately 7.7% of Haven Capital Group Inc.’s investment portfolio, making the stock its 4th largest position. Haven Capital Group Inc.’s holdings in IDEXX Laboratories were worth $8,211,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $30,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $31,000. Finally, Armstrong Advisory Group Inc. increased its stake in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Barclays lowered their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Piper Sandler reduced their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. UBS Group dropped their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Finally, BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Price Performance

IDXX stock opened at $558.32 on Monday. The firm has a 50 day moving average of $631.32 and a 200-day moving average of $662.08. The company has a market cap of $44.40 billion, a price-to-earnings ratio of 42.72, a PEG ratio of 3.39 and a beta of 1.66. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at $407,345.76. The trade was a 69.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP George Fennell sold 11,345 shares of the stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 45,957 shares of company stock worth $29,862,109. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.